Stimulants - Articles - Page 2

ADHD: Beyond Stimulants

August 15, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Richard Brown discusses symptoms that often get in the way of full recovery in ADHD, including dyslexia, and problems with working memory, processing speed, and executive function.

EXPERT Q&A

Personality Changes Later in Life: Diagnostic and Treatment Considerations

July 1, 2022

Rajesh R. Tampi, MD, MS, DFAPA.

Rajesh R. Tampi, MD

Professor and chairman, Department of Psychiatry, Bhatia Family Endowed Chair in Psychiatry, Creighton University School of Medicine. Catholic Health Initiatives (CHI) Behavioral Health Services, Omaha, NE.

Dr. Tampi, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Dr. Rajesh R. Tampi describes the course of personality disorders as patients age and provides documentation tips for clinicians who suspect personality disorders.

The Evidence Base for Polypharmacy in ADHD

March 24, 2022

Pavan Madan, MD.

Pavan Madan, MD. Dr. Madan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Often our patients with ADHD do not seem to respond adequately to one medication. We try different medications and we try combining them, but does it work? This study looked at the outcomes for stimulants alone and in combination with central alpha agonists, divalproex, and risperidone. Does polypharmacy work? Read it and see!

How to Treat ADHD in Bipolar Disorder

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.

Unpacking Aggression Associated with ADHD

October 18, 2021

John C. Blader, PhD

John C. Blader, PhD

Child and adolescent psychologist at the University of Texas Health Science Center, San Antonio, TX. Dr. Blader has disclosed that he has received funding from Supernus Pharmaceuticals for one research grant unrelated to this topic and these medications. Dr. Feder has reviewed this article and found no evidence of bias in this educational activity.

We often see children and teens who have ADHD with aggressive behavior. The press to treat them often results in polypharmacy with all the attendant risks and complications. This interview with Dr. Joseph Blader discusses research findings that can help us to provide more effective simplified and safer treatment for many of the patients.

Atomoxetine: Myths and Truths

September 10, 2021

Jason Mallo, DO

Jason Mallo, DO. Attending psychiatrist, Maine Medical Center, Portland, ME. Dr. Mallo has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

From ADHD to off-label uses, we detail how to dose atomoxetine, how pharmacogenomic testing affects it, and how it compares with stimulants and the other antidepressant for ADHD, viloxazine (Qelbree).

Pharmacotherapy for Stimulant Use Disorders

May 21, 2021

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are no approved pharmacotherapies for stimulant use disorders. Lots of medications have been studied and the results have been mixed. Here we provide you with the latest data, and some treatment recommendations.

Diagnosing and Treating Stimulant Use Disorders

May 21, 2021

Adriane dela Cruz, MD, PhD

Adriane dela Cruz, MD, PhD

Assistant Professor of Psychiatry at UT Southwestern Medical Center, Dallas, TX. Dr. dela Cruz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. de la Cruz gives advice for working with patients with addiction to prescription and illicit stimulants. She provides concrete strategies for diagnosis, harm reduction, evidence-based treatments, and contingency management in this challenging patient population.

The Other Pandemic

March 19, 2021

Predictions that overdose mortality would worsen during the COVID-19 pandemic have unfortunately proven accurate. Recent data outlined in an alert by the CDC show that rates of overdose deaths from opioids and stimulants have accelerated at an alarming rate.

Stimulants and Creativity

February 3, 2021

Sean Ransom, PhD.

Sean Ransom, PhD. Assistant Clinical Professor, Department of Psychiatry at the LSU Health Sciences Center - New Orleans, and Clinical Director, Cognitive Behavioral Therapy Center of New Orleans. Dr. Ransom has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Does ADHD bring creative strengths? Can stimulants dampen creative thought? New research suggests they can, but the effect varies by patient.